EMED Technologies Corp.'s SCIg60 Infusion System is the first Immune Globulin Subcutaneous (Human) mechanical pump infusion system to be approved by the U.S. Food and Drug Administration. Read More »
Pennsylvania Physician General Dr. Rachel Levine and Dauphin County Coroner Graham Hetrick recently met to discuss prescribing guidelines for opioids and benzodiazepines, known as benzos, and the opioid epidemic. Read More »
GSK has made a $139 million investment in a biopharmaceutical manufacturing site in Rockville, Maryland. Read More »
Teva Pharmaceutical Industries Ltd. will make a generic version of Vytorin (ezetimibe and simvastatin) available in America. Read More »
Teva Pharmaceutical Industries Ltd.'s results from a Phase II/III study ARM-TD (Aim to Reduce Movement in Tardive Dyskinesia) have been published in Neurology, the American Academy of Neurology's medical journal. Read More »
Mylan's Biologics License Application for MYL-1401H, a proposed biosimilar to Neulasta (pegfilgrastim), has been accepted by the U.S. Food and Drug Administration. Read More »
Genentech, a member of the Roche Group, recently announced its Phase II IMmotion150 study delivered promising results. Read More »
Teva Pharmaceutical Industries Ltd. has launched AirDuo RespiClick, an inhalation powder for the treatment of asthma in patients 12 and older. Read More »
Shire PLC has published results from its Phase 1b lanadelumab study in the New England Journal of Medicine. Read More »
GlaxoSmithKline (GSK) and Innoviva Inc. recently released positive results for a study evaluating Relvar Ellipta in treating asthma. Read More »
Shire PLC's Natpar, an adjunctive treatment for adult patients with chronic hypoparathyroidism, was reviewed positively by the Committee for Medicinal Products for Human Use of the European Medicines Agency. Read More »
Togo became the first country in Africa recognized by the World Health Organization for eliminating lymphatic filariasis, also known as elephantiasis, as a public health problem. Read More »
.jpg)
Shire's Vyvanse (lisdexamfetamine dimesylate) CII is now available in a chewable tablet formulation, making it the only Attention-Deficit/Hyperactivity Disorder and Binge Eating Disorder treatment available in five administration options. Read More »
A majority of the biggest patient advocacy groups in the country received drug industry funding last year, with many receiving as much as $1 million or more, a study has found. Read More »
Shire plc recently delivered data at the American Academy of Allergy, Asthma & Immunology annual meeting on its Cuvitru drug, which treats patients with primary immunodeficiency. Read More »
The voluntary recall of select lots of EpiPen Auto-Injectors and EpiPen Jr devices has been expanded. Read More »
To treat some of Huntington disease’s harshest symptoms and help restore quality of life to those suffering from the rare, fatal neurodegenerative disease, the U.S. Food and Drug Administration recently approved a medication created by Teva Pharmaceutical Industries. Read More »
Mylan N.V. has acquired the global rights to Cold-EEZE, a cold remedy line of products, from ProPhase Labs Inc. Read More »
Mylan N.V. recently released a brief statement regarding the status of its Abbreviated New Drug Application for its generic iteration of GlaxoSmithKline's Advair Diskus bronchodilator product. Read More »
Shire PLC's recombinant ADAMTS13 drug, SHP655, has been given fast-track designation by the U.S. Food and Drug Administration. Read More »
Alerts Sign-up
